Prothena (NASDAQ: PRTA) posts $32.7M Q1 profit and lifts 2026 cash outlook
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Prothena Corporation plc reported strong first quarter 2026 results, with total revenue of $51.1 million and net income of $32.7 million, compared with a net loss of $60.2 million a year earlier. Results were driven mainly by a $50 million milestone payment from Novo Nordisk and lower research and development and general and administrative expenses, plus a $4.2 million restructuring credit.
Quarter-end cash, cash equivalents and restricted cash were $330.3 million and the company had no debt. Prothena cut its projected 2026 net cash used in operating and investing activities to $18–$23 million and now expects to end 2026 with about $273 million in cash (midpoint). It also authorized a 2026 share repurchase program for up to $100 million, repurchasing 788,990 shares for $7.3 million through March 31, 2026.
Operationally, Novo Nordisk obtained U.S. FDA Fast Track designation for coramitug and paid the $50 million milestone, Roche presented multiple positive prasinezumab data updates, Prothena completed a Phase 1 study for PRX019 with potential for a $55 million milestone from Bristol Myers Squibb, and preclinical CYTOPE and PRX012-TfR programs continued to advance.
Positive
- Return to profitability and major revenue growth: Q1 2026 revenue rose to $51.1 million and net income reached $32.7 million, compared with a $60.2 million net loss on $2.8 million of revenue a year earlier, driven largely by a $50 million Novo Nordisk milestone and lower operating expenses.
- Stronger 2026 cash outlook: Projected full-year 2026 net cash used in operating and investing activities was reduced to $18–$23 million from prior guidance of $50–$55 million, and expected year-end cash (midpoint) increased to approximately $273 million from $255 million.
- Non-dilutive funding from partnerships: Prothena received a $50 million clinical milestone payment from Novo Nordisk in Q1 2026 and could potentially earn an additional $55 million milestone in 2026 if Bristol Myers Squibb advances the PRX019 program.
- Capital return via buybacks: The company initiated a 2026 share repurchase program of up to $100 million and had already repurchased 788,990 ordinary shares for $7.3 million (excluding commissions and expenses) as of March 31, 2026.
Negative
- None.
Insights
Q1 2026 shows a sharp move to profitability, stronger cash outlook, and milestone-driven revenue.
Prothena delivered net income of $32.7 million on total revenue of $51.1 million in Q1 2026, versus a $60.2 million loss a year earlier. The quarter was dominated by a $50 million clinical milestone payment from Novo Nordisk and substantially lower R&D and G&A expenses.
Ending cash, cash equivalents and restricted cash reached $330.3 million with no debt, and management reduced 2026 net cash used in operating and investing activities to $18–$23 million. They now expect to end 2026 with about $273 million in cash (midpoint), while guiding to a $25–$30 million net loss including $26 million of non-cash share-based compensation.
A share repurchase program of up to $100 million is in place, with $7.3 million used to repurchase 788,990 shares in Q1. Future financial performance will depend heavily on additional milestone receipts, collaboration revenue from partnered programs, and execution of the expanded preclinical and clinical pipeline described for 2026 and beyond.
Partnered Phase 3 programs advanced, adding non-dilutive funding and potential future milestones.
The quarter highlighted partnered assets. Novo Nordisk obtained U.S. FDA Fast Track designation for coramitug for ATTR-CM and paid a $50 million Phase 3 enrollment milestone. Roche presented multiple prasinezumab data sets and is running the Phase 3 PARAISO trial, with primary completion expected in 2029.
Bristol Myers Squibb is conducting the Phase 2 TargetTau-1 trial for BMS-986446 and a Phase 1 subcutaneous study, both with Fast Track designation. Prothena completed a Phase 1 study for PRX019 and could earn a $55 million milestone if BMS advances it by year-end 2026. Preclinical TDP-43 CYTOPE and PRX012-TfR programs also progressed with new presentations and ongoing studies.
These collaborations provide important external validation and non-dilutive economics, but actual financial impact will depend on future trial outcomes, regulatory decisions and partner development choices over the next several years.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Q1 2026 total revenue: $51.1 million
Q1 2026 net income: $32.7 million
Novo Nordisk milestone payment: $50.0 million
+5 more
8 metrics
Q1 2026 total revenue
$51.1 million
Three months ended March 31, 2026
Q1 2026 net income
$32.7 million
Three months ended March 31, 2026
Novo Nordisk milestone payment
$50.0 million
Phase 3 enrollment for coramitug in Q1 2026
Quarter-end cash and restricted cash
$330.3 million
As of March 31, 2026; no debt outstanding
2026 net cash used guidance
$18–$23 million
Projected full-year 2026 operating and investing activities
Expected 2026 year-end cash
$273 million
Midpoint projected cash, cash equivalents and restricted cash
Share repurchase program size
$100.0 million
Authorized repurchases to be conducted in 2026, expiring December 31, 2026
Shares repurchased in Q1 2026
788,990 shares for $7.3 million
Through March 31, 2026, excluding commissions and expenses
Key Terms
Fast Track designation, share repurchase program, non-cash share-based compensation, restructuring credit, +2 more
6 terms
Fast Track designation regulatory
"Novo Nordisk obtained Fast Track designation from the U.S. FDA for coramitug (PRX004) for the treatment of ATTR amyloidosis with cardiomyopathy"
A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.
restructuring credit financial
"Prothena recorded an aggregate restructuring credit of approximately $4.2 million for the three months ended March 31, 2026"
Phase 3 clinical trial technical
"Novo Nordisk is conducting the Phase 3 CLEOPATTRA clinical trial in approximately 1280 participants with ATTR-CM"
A phase 3 clinical trial is a large-scale study that tests a new medical treatment or drug to determine if it is safe and effective for widespread use. It often involves hundreds or thousands of participants and compares the new treatment to existing options or a placebo. For investors, the results of this phase are crucial, as successful outcomes can lead to regulatory approval and commercial success, while failures may halt development.
CYTOPE® technology technical
"Prothena is developing and applying CYTOPE®, a novel technology that incorporates a cell-internalizing domain"
Earnings Snapshot
Total revenue: $51.1 million · Guidance included
Q1 2026
Total revenue
$51.1 million
Net income
$32.7 million
Quarter-end cash and restricted cash
$330.3 million
Projected 2026 net cash used (operating & investing)
$18–$23 million
Expected year-end 2026 cash (midpoint)
$273 million
Guidance
For 2026, Prothena projects net cash used in operating and investing activities of $18–$23 million, an estimated net loss of $25–$30 million including $26 million of non-cash share-based compensation, and expects to end the year with approximately $273 million in cash, cash equivalents and restricted cash.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________________________________________
FORM 8-K
_______________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 7, 2026
_______________________________________________________
(Exact name of registrant as specified in its charter)
_______________________________________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||||||||
| (Address of principal executive offices, including Zip Code) | ||||||||||||||||||||
Registrant’s telephone number, including area code: 011-353 -1 -236-2500
___________________________________________________
(Former Name or Former Address, if Changed Since Last Report.)
___________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02. | Results of Operations and Financial Condition. | ||||
The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically incorporate by reference the information furnished pursuant to Item 2.02 (including Exhibit 99.1) of this Current Report.
On May 7, 2026, Prothena Corporation plc issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of that press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01. | Financial Statements and Exhibits | ||||
(d) Exhibits.
| Exhibit No. | Description | |||||||
| 99.1 | Press Release dated May 7, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: | May 7, 2026 | PROTHENA CORPORATION PLC | ||||||||||||
| By: | /s/ Tran B. Nguyen | |||||||||||||
| Name: | Tran B. Nguyen | |||||||||||||
| Title: | Chief Financial Officer | |||||||||||||
Exhibit 99.1
PRESS RELEASE
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
•Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million
•Prothena updates projected full year 2026 net cash used in operating and investing actives to be $18 to $23 million (versus prior guidance $50 to $55 million) and expects to end the year with approximately $273 million (midpoint) in cash, cash equivalents and restricted cash
•Novo Nordisk obtained Fast Track designation from the U.S. FDA for coramitug (PRX004) for the treatment of ATTR amyloidosis with cardiomyopathy and paid Prothena a $50 million clinical milestone payment related to Phase 3 enrollment
•Roche presented several clinical updates supporting the potential of prasinezumab for the treatment of Parkinson’s disease at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026)
•Prothena has completed the Phase 1 study for PRX019. Prothena could potentially earn a $55 million clinical milestone payment if Bristol Myers Squibb decides to advance the program; BMS decision expected by year-end 2026
•Prothena initiated a share repurchase program to be conducted in 2026 for up to $100 million if deemed appropriate
DUBLIN, Ireland, May 7, 2026 -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2026 and provided business highlights.
“In the quarter we were encouraged by updates on our partnered Phase 3 clinical programs. Roche delivered several presentations highlighting the potential of prasinezumab for Parkinson’s disease at AD/PD 2026, including a ‘time saved’ analysis demonstrating approximately two years in delay of disease progression over a five year period from the PASADENA open-label extension study, longer-term data from the PADOVA open-label extension study showing a sustained effect of prasinezumab on disease progression, and exploratory biomarker analyses of the PADOVA trial suggesting that prasinezumab may impact the underlying disease biology. Novo Nordisk recently obtained Fast Track designation from the U.S. FDA for coramitug in ATTR-CM and delivered $50 million to Prothena upon achievement of a Phase 3 clinical milestone,” said Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena. “In addition, we are engaged in multiple research collaborations with industry partners exploring the potential of our CYTOPE® technology. Finally, our team continues to explore additional research collaborations and licensing partnerships to further advance our programs.”
Business Highlights and Upcoming Milestones
Active Clinical Development Portfolio
Prasinezumab, a potential first-in-class antibody for the treatment of Parkinson’s disease that is designed to target a key epitope within the C-terminus of alpha-synuclein and is the focus of a worldwide collaboration with Roche.
•Partner Roche presented several clinical updates from the Phase 2b PADOVA trial and open-label extension (OLE) and the PASADENA OLE study supporting the potential of prasinezumab for the treatment of Parkinson’s disease at AD/PDTM 2026
◦Oral Presentation – Modeling Parkinson’s Disease Progression to Quantify Long-Term Treatment Effects via the Concept of ‘Time Saved’
◦Oral Presentation – Prasinezumab in Early-Stage Parkinson’s Disease: Additional Data from the PADOVA Study
◦Poster Presentation – Prasinezumab’s Impact on Neuromelanin- and Iron-Sensitive MRI Biomarkers in Parkinson’s Disease: Findings from the PADOVA Phase IIb Study
◦Poster Presentation – Sustained Effect on Prasinezumab on Parkinson’s Disease Motor Progression in the Open-Label Extension of the PASADENA Trial, 5-Year Update
◦Poster Presentation – Digital Health Technology Detects Group Differences in Practically-Defined OFF L-DOPA State: Results of PADOVA Phase IIb Study of Prasinezumab
•Roche is conducting the Phase 3 PARAISO clinical trial in approximately 900 participants with early-stage Parkinson's disease; primary completion expected in 2029 (NCT07174310)
•Roche has stated that prasinezumab has peak sales potential greater than $3.5 billion (unadjusted) and could be the first disease-modifying treatment for a condition that affects 10 million people worldwide
Coramitug (formerly PRX004), a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) designed to deplete the pathogenic, non-native forms of the transthyretin (TTR) protein, is being developed by Novo Nordisk as part of its up to $1.2 billion acquisition of Prothena’s ATTR amyloidosis business and pipeline.
•Novo Nordisk is conducting the Phase 3 CLEOPATTRA clinical trial in approximately 1280 participants with ATTR-CM; primary completion expected in 2029 (NCT07207811)
•Coramitug granted Fast Track designation from the U.S. FDA for the treatment of ATTR-CM
•Novo Nordisk initiated an open-label study to evaluate the biodistribution of 89Zr-coramitug and investigate the effects of coramitug on depleting TTR amyloid deposits in myocardial tissues using PET/CT imaging in participants with ATTR-CM; primary completion expected in 2027 (NCT07448623)
•Prothena received a $50 million clinical milestone payment related to Phase 3 enrollment
BMS-986446 (formerly PRX005), a potential best-in-class antibody for the treatment of Alzheimer’s disease that specifically targets a key epitope within the microtubule binding region (MTBR) of tau, a protein implicated in the causal pathophysiology of Alzheimer’s disease.
•Bristol Myers Squibb is conducting the Phase 2 TargetTau-1 clinical trial in approximately 310 patients with early Alzheimer’s disease; primary completion expected in 1H 2027 (NCT06268886)
•Bristol Myers Squibb conducted a Phase 1 open-label single-dose clinical trial to assess a subcutaneous administration (NCT06955741)
•BMS-986446 granted Fast Track designation by U.S. FDA as a treatment for Alzheimer’s disease
PRX019, a potential treatment of neurodegenerative diseases in development in collaboration with Bristol Myers Squibb.
•Prothena has completed a Phase 1 study to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of single ascending and multiple doses in healthy adults
•Prothena could potentially earn a $55 million clinical milestone payment if Bristol Myers Squibb decides to advance the program; BMS decision expected by YE 2026
Active Preclinical Development Portfolio
TDP-43 CYTOPE®, a wholly-owned proprietary preclinical program for precision intracellular targeting of TDP-43 pathology, a defining pathogenic feature of ALS and other TDP-43 proteinopathies. TDP-43 CYTOPE preclinical data demonstrates the potential of Prothena’s CYTOPE® technology to target intracellular disease pathways.
•Prothena presented a poster at Neuroscience 2025 (Society for Neuroscience) and the International Symposium of ALS/MND demonstrating the potential of TDP-43 CYTOPE in multiple preclinical models
PRX012-TfR, a wholly-owned preclinical program combining PRX012, our single-injection, once-monthly antibody delivered subcutaneously with proprietary transferrin receptor technology to potentially improve its product profile.
•Preclinical studies ongoing to support potential efficacy of PRX012-TfR
Upcoming Investor Conference
Members of the senior management team will participate in 1 on 1 investor meetings at the following upcoming investor conference:
•H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 in New York, NY
First Quarter of 2026 Financial Results
For the first quarter of 2026, Prothena reported net income of $32.7 million, as compared to a net loss of $60.2 million for the first quarter of 2025. Basic net income per share was $0.61 and fully dilutive net income per share was $0.60 for the first quarter of 2026, as compared to a basic and dilutive net loss per share of $1.12 for the first quarter of 2025.
Prothena reported total revenue of $51.1 million for the first quarter of 2026, as compared to total revenue of $2.8 million for the first quarter of 2025. Total revenue for the first quarter of 2026 was primarily from $50.0 million in milestone payment from Novo Nordisk related to ongoing Phase 3 clinical trial for coramitug and collaboration revenue from Bristol Myers Squibb related to the partial performance of our PRX019 Phase 1 clinical trial obligation. Total revenue for the first quarter of 2025, was primarily from collaboration revenue from Bristol Myers Squibb related to the partial performance of our PRX019 Phase 1 clinical trial obligation.
Research and development (R&D) expenses totaled $12.6 million for the first quarter of 2026, as compared to $50.8 million for the first quarter of 2025. The decrease in R&D expenses for the first quarter of 2026 compared to the same periods in the prior year was primarily due to lower clinical trial expenses, lower personnel expenses, lower manufacturing expenses and lower consulting expenses. R&D expenses included non-cash share-based compensation expense of $2.0 million for the first quarter of 2026, as compared to $4.8 million for the first quarter of 2025.
General and administrative (G&A) expenses totaled $12.7 million for the first quarter of 2026, as compared to $17.6 million for the first quarter of 2025. The decrease in G&A expenses for the first quarter of 2026 compared to the same periods in the prior year was primarily due to lower consulting expenses and lower personnel expenses. G&A expenses included non-cash share-based compensation expense of $4.9 million for the first quarter of 2026, as compared to $6.1 million for the first quarter of 2025.
Prothena recorded an aggregate restructuring credit of approximately $4.2 million for the three months ended March 31, 2026 primarily related to a reduction in contract termination costs associated with one or more third-party vendors.
Total non-cash share-based compensation expense was $6.9 million for the first quarter of 2026, as compared to $10.9 million for the first quarter of 2025.
As of March 31, 2026, Prothena had $330.3 million in cash, cash equivalents and restricted cash, and no debt.
As of April 30, 2026, Prothena had approximately 52.4 million ordinary shares outstanding.
2026 Financial Guidance
Prothena is updating its projected full year 2026 net cash used in operating and investing actives, and expects it to be $18 to $23 million (versus prior guidance $50 to $55 million) and expects to end the year with approximately $273 million (midpoint) in cash, cash equivalents and restricted cash, representing an increase of $18 million from prior guidance of $255 million (midpoint). This increase in cash position is primarily driven by a $50 million milestone payment from Novo Nordisk related to the advancement of coramitug offset by cash utilized as part of share repurchase program activities of approximately $15 million through April 30, 2026, the settlement of liabilities related to discontinued programs, and an increased investment in our preclinical programs. The updated estimated full year 2026 net cash used from operating and investing activities is primarily driven by an updated estimated net loss of $25 to $30 million (versus prior guidance of $67 to $72 million), which includes an estimated $26 million of non-cash share-based compensation expense. This financial guidance does not include the potential to earn a $55 million clinical milestone payment in 2026 related to the advancement of PRX019 for neurodegenerative diseases by Bristol Myers Squibb or additional cash utilized as part of a share repurchase program.
1Q 2026 Share Repurchase Program
Prothena repurchased a total of 788,990 ordinary shares with $7.3 million, exclusive of commissions and expenses, as of March 31, 2026, from its up to $100.0 million share repurchase program, which expires December 31, 2026.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases. Prothena is developing and applying CYTOPE®, a novel technology that incorporates a cell-internalizing domain to drive efficient cytosolic delivery with highly specific marcomolecular effectors. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to, among other things, the sufficiency of our cash position to fund advancement of our pipeline and completion of our ongoing clinical trials; the continued advancement of our preclinical and clinical pipeline, including the potential and advancement of our CYTOPE technology and expected milestones in 2026, 2027, and beyond; the treatment potential, designs, proposed mechanisms of action, and potential administration of prasinezumab, coramitug, BMS-986446, PRX019, TDP-43 CYTOPE, and PRX012-TfR; plans for ongoing and future clinical trials of prasinezumab, coramitug, BMS-986446, and PRX019; the expected timing of reporting data from preclinical studies and clinical trials; projections regarding peak sales and patient population for prasinezumab; timing of and amounts we may receive under our collaborations with Novo Nordisk and Bristol Myers Squibb; our anticipated net cash burn from operating and investing activities for 2026 and expected cash balance at the end of 2026; our estimated net loss and non-cash share-based compensation expense for 2026; and the potential to return capital to shareholders via a share repurchase program or other permissible means. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to those described in the “Risk Factors” sections of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 7, 2026, and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events, or changes in our expectations.
PROTHENA CORPORATION PLC
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited - amounts in thousands except per share data)
| Three Months Ended March 31, | ||||||||||||||
| 2026 | 2025 | |||||||||||||
| Collaboration revenue | $ | 1,034 | $ | 2,778 | ||||||||||
| Revenue from license and intellectual property | 50,050 | 50 | ||||||||||||
| Total revenue | 51,084 | 2,828 | ||||||||||||
| Operating expenses: | ||||||||||||||
| Research and development | 12,627 | 50,811 | ||||||||||||
| General and administrative | 12,666 | 17,598 | ||||||||||||
| Restructuring costs | (4,244) | — | ||||||||||||
| Total operating expenses | 21,049 | 68,409 | ||||||||||||
Income (loss) from operations | 30,035 | (65,581) | ||||||||||||
| Other income, net | 2,687 | 4,208 | ||||||||||||
Income (loss) before income taxes | 32,722 | (61,373) | ||||||||||||
| Provision for (benefit from) income taxes | 1 | (1,178) | ||||||||||||
Net income (loss) | $ | 32,721 | $ | (60,195) | ||||||||||
| Basic net income (loss) per ordinary share | $ | 0.61 | $ | (1.12) | ||||||||||
| Diluted net income (loss) per ordinary share | $ | 0.60 | $ | (1.12) | ||||||||||
| Shares used to compute basic net income (loss) per share | 53,708 | 53,827 | ||||||||||||
| Shares used to compute diluted net income (loss) per share | 54,109 | 53,827 | ||||||||||||
PROTHENA CORPORATION PLC
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited - amounts in thousands)
| March 31, | December 31, | ||||||||||
| 2026 | 2025 | ||||||||||
| Assets | |||||||||||
| Cash and cash equivalents | $ | 329,462 | $ | 307,531 | |||||||
| Prepaid expenses and other current assets | 9,739 | 7,662 | |||||||||
| Total current assets | 339,201 | 315,193 | |||||||||
| Property and equipment, net | 1,960 | 2,144 | |||||||||
| Operating lease right-of-use assets | 7,391 | 8,125 | |||||||||
| Restricted cash, non-current | 860 | 860 | |||||||||
| Other non-current assets | 482 | 482 | |||||||||
| Total non-current assets | 10,693 | 11,611 | |||||||||
| Total assets | $ | 349,894 | $ | 326,804 | |||||||
| Liabilities and Shareholders’ Equity | |||||||||||
| Accrued research and development | $ | 4,611 | $ | 4,329 | |||||||
Deferred revenue, current | 1,630 | 2,664 | |||||||||
Restructuring liability | 8,585 | 13,303 | |||||||||
| Lease liability, current | 2,893 | 2,886 | |||||||||
| Other current liabilities | 14,798 | 17,661 | |||||||||
| Total current liabilities | 32,517 | 40,843 | |||||||||
| Lease liability, non-current | 4,761 | 5,487 | |||||||||
Total non-current liabilities | 4,761 | 5,487 | |||||||||
| Total liabilities | 37,278 | 46,330 | |||||||||
| Total shareholders’ equity | 312,616 | 280,474 | |||||||||
| Total liabilities and shareholders’ equity | $ | 349,894 | $ | 326,804 | |||||||
Contacts:
Mark Johnson, CFA
Senior Vice President, Head of Investor Relations and Corporate Communications
650-837-8550
IR@prothena.com
Media@prothena.com
FAQ
How did Prothena (PRTA) perform financially in the first quarter of 2026?
Prothena reported net income of $32.7 million for Q1 2026, compared with a net loss of $60.2 million a year earlier. Total revenue increased to $51.1 million from $2.8 million, mainly from a $50 million milestone payment and collaboration revenue.
What is Prothena’s 2026 cash and net loss guidance after Q1 2026 results?
Prothena now expects 2026 net cash used in operating and investing activities of $18–$23 million and an estimated year-end cash balance of about $273 million (midpoint). The updated outlook includes an estimated net loss of $25–$30 million with $26 million of non-cash share-based compensation.
How much cash does Prothena (PRTA) have and does it carry any debt?
As of March 31, 2026, Prothena held $330.3 million in cash, cash equivalents and restricted cash, and reported no debt. This strong balance sheet supports ongoing clinical trials, preclinical programs, and capital return activities described for 2026.
What milestone payments did Prothena receive or potentially earn in 2026?
In Q1 2026, Prothena received a $50 million clinical milestone payment from Novo Nordisk related to the Phase 3 coramitug trial. It could also earn a $55 million clinical milestone payment if Bristol Myers Squibb decides to advance PRX019 by year-end 2026.
Which key partnered programs are highlighted in Prothena’s Q1 2026 update?
Key programs include prasinezumab for Parkinson’s disease with Roche, coramitug (PRX004) for ATTR-CM with Novo Nordisk, and BMS-986446 and PRX019 with Bristol Myers Squibb. Several have Fast Track designation and are in Phase 2 or Phase 3 development.
What are Prothena’s main R&D spending trends in Q1 2026?
Research and development expenses fell to $12.6 million in Q1 2026 from $50.8 million a year earlier, driven by lower clinical trial, personnel, manufacturing, and consulting costs. R&D included $2.0 million of non-cash share-based compensation, down from $4.8 million.